Skip to main content

#161792

C1.1 cell line

Cat. #161792

C1.1 cell line

Cat. #: 161792

Availability: 8-10 weeks

Organism: Human

Tissue: Skin

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Christoper Stipp

Institute: University Of Iowa Research Foundation

Primary Citation: Feddersen et al.2019. Cancer Res. 79(19). PMID: 31416844

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: C1.1 cell line
  • Alternate name: C1.1
  • Cancer: Skin cancer
  • Research fields: Cancer;Drug development
  • Parental cell: A375 Melanoma (ATCC)
  • Organism: Human
  • Gender: Female
  • Tissue: Skin
  • Donor: A375 (ATCC) -human melanoma cell line of a solid tumor from a 54-year-old female.
  • Morphology: Compact Morphology
  • Description: Spontaneous vemurafenib resistant A375 Melanoma Clones. Shows frequent alterations of BRAF^V600 protein. No increased VAV1 protein levels.
  • Production details: Long-term cultures of A375 cells in 3 ?M vemurafenib. Spontaneous vemurafenib-resistant clones and populations were created after 2–3 and 4–6 weeks cultured in 3 mm vemurafenib. Maintained in media with 3 mm vemurafenib.

Handling

  • Growth medium: DMEM(Gibco) suplemented with penicillin/streptomycin (Gibco) and 10% FBS (Gibco).
  • Shipping conditions: Dry Ice

References

  • Feddersen et al.2019. Cancer Res. 79(19).PMID: 31416844
  • Zhu et al. 2022. npj Precis. Onc. PMID: 36271142

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.